Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Toyama, R.
Right arrow Articles by Fujiki, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Toyama, R.
Right arrow Articles by Fujiki, Y.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Isolation, characterization and mutation analysis of <I>PEX13</I>-defective Chinese hamster ovary cell mutants
Human Molecular Genetics Pages 1673-1681 ©1999 Oxford University Press


Isolation, characterization and mutation analysis of PEX13-defective Chinese hamster ovary cell mutants
Introduction
Results
   Isolation and complementation group analysis of CHO cell mutants
   PEX13 restored peroxisome biogenesis in ZP128
   Dysfunction of Pex13p in CHO mutants
   Characterization of PEX13 protein
Discussion
Materials And Methods
   Isolation of peroxisome-deficient CHO cell mutants and CG analysis
   Stable transfection of PEX13 and expression of flag-tagged Pex13p
   Screening of a Chinese hamster cDNA library and mutation analysis
   Other methods
Abbreviations
Acknowledgements
References


Isolation, characterization and mutation analysis of PEX13-defective Chinese hamster ovary cell mutants

Ryusuke Toyama1, Satoru Mukai1, 2, Atsushi Itagaki1, Shigehiko Tamura1, Nobuyuki Shimozawa3, Yasuyuki Suzuki3, Naomi Kondo3, Ronald J. A. Wanders4, Yukio Fujiki1, 2, +

1Department of Biology, Kyushu University Graduate School of Science, Fukuoka 812-8581, Japan, 2CREST, Japan Science and Technology Corporation, Tokyo, 170-0013, Japan, 3Department of Pediatrics, Gifu University Faculty of Medicine, Gifu 500-8076, Japan and 4Department of Clinical Biochemistry and Pediatrics, Academic Medical Centre, University of Amsterdam, PO Box 22700, 1100DE, Amsterdam, The Netherlands

Received March 10, 1999; Revised and Accepted June 7, 1999

We isolated peroxisome biogenesis mutants ZP128 and ZP150 from rat PEX2-transformed Chinese hamster ovary (CHO) cells, by the 9-(1[prime]-pyrene)nonanol/ultraviolet method. The mutants lacked morphologically recognizable peroxisomes and showed a typical peroxisome assembly-defective phenotype such as a high sensitivity to 12-(1[prime]-pyrene)dodecanoic acid/UV treatment. By means of PEX cDNA transfection and cell fusion, ZP128 and ZP150 were found to belong to a recently identified complementation group H. Expression of human PEX13 cDNA restored peroxisome assembly in ZP128 and ZP150. CHO cell PEX13 was isolated; its deduced sequence comprises 405 amino acids with 93% identity to human Pex13p. Mutation in PEX13 of mutant ZP150 was determined by RT-PCR: G to A transition resulted in one amino acid substitution, Ser319Asn, in one allele and truncation of a 42 amino acid sequence from Asp265 to Lys306 in another allele. Therefore, ZP128 and ZP150 are CHO cell lines with a phenotype of impaired PEX13.

INTRODUCTION

Peroxisomes are formed by division of pre-existing peroxisomes after post-translational import of newly synthesized proteins (1). Recent evidence obtained by studies using yeast mutants suggests the involvement of the endoplasmic reticulum (ER) in peroxisomal membrane biogenesis (2). Cis-acting peroxisomal targeting signals (PTSs) have been identified: a C-terminal SKL tripeptide motif (PTS1) and an N-terminal cleavable presequence (PTS2) of several proteins such as 3-ketoacyl-CoA thiolase (3). Genetic analysis of peroxisome-deficient mutants of yeast and mammalian cells has led to the identification of a number of protein factors, peroxins, essential for peroxisome biogenesis (3,4). The functional significance of human peroxisomes is highlighted by fatal genetic diseases linked to peroxisomal malfunction and failure of peroxisome biogenesis (3).

We previously isolated and characterized eight, mutually distinct Chinese hamster ovary (CHO) cell mutants, such as ZP65 (5) and ZP119 (6), and recently have isolated ZP126 (7). More than 15 genes are likely to be involved in mammalian peroxisome assembly, as deduced from complementation group (CG) analyses of CHO cell mutants and fibroblasts from patients with various peroxisome biogenesis disorders (PBD) (3,6,7). We isolated several PEX cDNAs, including PEX1, PEX2 (formerly PAF-1), PEX12 and PEX19, by genetic phenotype complementation assay of such CHO cell mutants, and further demonstrated that these PEX genes are responsible for the primary defects in PBD patients (8-12). Thus, peroxisome biogenesis-defective CHO cell mutants are an excellent mammalian somatic cell system for investigation of peroxisome assembly at the molecular and cellular levels, as well as for delineation of the genetic basis of PBD (3).

In this study, we isolated two novel peroxisome-deficient CHO cell mutants, ZP128 and ZP150, both belonging to CG-H (13). Transfection of PEX13 cDNA restored peroxisome biogenesis in ZP128, indicating that ZP128 and ZP150 are CHO cell lines with a phenotype of impaired PEX13. Mutation analysis of PEX13 in ZP150 is also reported.

RESULTS

Isolation and complementation group analysis of CHO cell mutants

By using the 9-(1[prime]-pyrene)nonanol/ultraviolet (P9OH/UV) selection method, we isolated 10 CHO cell mutant clones showing catalase in a diffuse staining pattern in the cytosol, as seen in ZP128 and ZP150 (Fig. 1A, a and e), indicative of a defect in peroxisome biogenesis (6,14) (Table 1). One mutant, ZP130, contained catalase-positive but morphologically aberrant, tube-like structures (data not shown), as in several earlier mutants (6,15). Mutant ZP128 apparently in a novel CG (see below) was stained with antibodies to PTS1 and 3-ketoacyl-CoA thiolase, a PTS2 protein (16). PTS1 proteins were visualized in punctate structures, presumably peroxisomes, in nearly half of the cells (Fig. 1A, b), while thiolase was present in the cytosol in most cells (Fig. 1A, c). Thus, import of PTS1 proteins appears to be mildly affected and PTS2 transport is more severely impaired in ZP128. Temperature-sensitive restoration of the impaired peroxisome biogenesis (17), revealed in fibroblasts from a CG-H patient with neonatal adrenoleukodystrophy (13), was not observed in ZP128 and ZP150 (data not shown). Peroxisomal remnants were seen in ZP128 (Fig. 1A, d), as in earlier CHO cell mutants (3,18) and fibroblasts from PBD patients (19,20). ZP150 in the same CG as ZP128 (see below) also showed such a morphological phenotype.


Figure 1. Immunofluorescent staining of CHO cell mutants, PEX transfectants and hybrid cells. (A) Cells: (a-d) CHO cell mutant ZP128; (e) ZP150; (f and g) ZP149 and ZP128 were transfected with rat PEX12; (h) fusion of ZP128 with ZP150 cells; (i and j) fused cells of ZP150 with ZP114 and ZP119, respectively; (k and l) cell hybrids of ZP128 and ZP150, respectively, with wild-type CHO-K1. Cells were stained with rabbit antibodies to rat catalase (a and e-l), PTS1 peptide (b), rat thiolase (c) and rat 70 kDa peroxisomal integral membrane protein (d). Magnification, ×630; bar, 20 µm. (B) ZP128 cells were fused with fibroblasts from a CG-H patient with neonatal adrenoleukodystrophy (13) (a) and a CG-G patient with Zellweger syndrome (b), respectively. Cells were stained with anti-human catalase antibody. Magnification, ×630; bar, 30 µm. Note that peroxisomes were not complemented in (a).

Table 1. CG analysis
CHO mutant PEX2 PEX5 PEX6 PEX12      
PEX cDNA transfection assay              
ZP128 - - - -      
ZP129 - - - -      
ZP143 + - - -      
ZP144 - + - -      
ZP145 - - - -      
ZP146 - - - -      
ZP147 + - - -      
ZP148 + - - -      
ZP149 - - - +      
ZP150 - - - -      
CHO mutant Z24 ZP110 ZP114 ZP119 ZP124a ZP126a ZP128
Cell fusion assay              
ZP128 + + + + + + -
ZP129 + + + + - + +
ZP145 -            
ZP146 -            
ZP150 + + + + + + -
CHO cell mutants were transfected separately with rat PEX2 (9), human PEX5 (21), rat PEX6 (22) and rat PEX12 (11). Cells were stained with anti-catalase antibody. +, peroxisomes were complemented;-, not complemented.
aFrom Ghaedi et al. (7).

To determine the CGs of 10 CHO mutants, each cell clone was transfected with PEX2, PEX5, PEX6 and PEX12 cDNAs (Table 1). ZP149, but not others including ZP128, was restored in catalase import by PEX12 (Fig. 1A, f and g), thus indicating that ZP149 belonged to CG-III (11). Three mutants were found to be in a PEX2-deficient CG (9), implying that introduced PEX2 cDNA was probably disintegrated during the initial cultivation of TKa (6); one mutant was in PEX5-defective CG (21). None of the mutants was in a PEX6-defective CG (22). Accordingly, it is apparent that CHO mutants ZP128, ZP129, ZP145, ZP146 and ZP150 belong to CG(s) different from these four CGs. Next, these five unclassified cell mutants were examined by cell fusion. ZP145 and ZP146 were revealed to be in CG-E (CG-I in the USA). ZP129 was in the same CG as recently isolated ZP124 (7). ZP128 and ZP150 were both complemented by cell fusion with all cell mutants examined (Fig. 1A, i and j) (Table 1), except for a cell hybrid between ZP128 and ZP150 (Fig. 1A, h). Taken together, we conclude that ZP128 and ZP150 are in the same CG but distinct from any of the previously identified CGs of CHO mutants. Moreover, fused cells of ZP128 and ZP150 each with the wild-type CHO-K1 showed catalase-positive particles (Fig. 1A, k and l), indicating that lesion(s) of allele(s) in the mutants are recessive, as in earlier cell mutants (3). Furthermore, no evidence of re-establishment of peroxisomes was obtained by cell fusion of ZP128 with fibroblasts from a CG-H patient (13) (Fig. 1B, a). In contrast, numerous peroxisomes were evident in the respective hybrid cells of ZP128 with CG-G (23) (Fig. 1B, b) and CG-VI (data not shown) for which no complementing genes are yet elucidated. Accordingly, these results strongly suggested that ZP128 and ZP150 are classified in CG-H.

PEX13 restored peroxisome biogenesis in ZP128

Genetic functional complementation assay (8) of ZP128 using a human liver cDNA library led us to isolate first a positive clone containing an open reading frame (ORF) apparently encoding a 39 amino acid shorter Pex13p (24) (Fig. 2A, a), and then a full-length human (Hs) PEX13 (13,25) (Fig. 2A, b) at a later stage of the present work. The HsPEX13 complemented peroxisomal import of catalase in both ZP128 (see below) and ZP150 (data not shown). Several phenotypic abnormalities due to the peroxisome deficiency were found in ZP128 (see below), as in earlier CHO mutants (5,6,14,18). A stable HsPEX13 transformant of ZP128, named 128P13, showed peroxisomal localization of catalase, PTS1 proteins and PTS2 3-ketoacyl-CoA thiolase (data not shown). Restoration of catalase import was also verified by the digitonin titration method (5). About 70% of the catalase activity was latent at 100 µg/ml of digitonin in 128P13, as in CHO-K1, but ZP128 showed no latency (Fig. 2B, a). HsPEX13 expression also complemented peroxisome assembly in ZP150, but not in eight other CHO mutants and in five CGs of PBD patient fibroblasts (Table 2). Moreover, expression of Chinese hamster PEX13 (see below) restored peroxisome biogenesis in ZP150 (Fig. 2A, c). These data indicate that Pex13p is the peroxisome biogenesis factor for ZP128 and ZP150 of CG-H.


Figure 2. Restoration of peroxisomes in CG-H CHO mutant cells. (A) (a) ZP128 was transfected with an HsPEX13 clone encoding the N-terminal 39 amino acid truncated Pex13p (see text). The arrow indicates a complemented cell. (b) ZP128 transfected with pUcD2Hyg·HsPEX13. (c) ZP150 was transfected with Chinese hamster PEX13, pUcD2Hyg·ClPEX13. Cells were stained with anti-catalase antibody. Magnification, ×630; bar, 20 µm. (B) Complementation of biogenesis of peroxisomal enzymes. (a) Latency of catalase activity in CHO-K1, ZP128 and 128P13 cells. Circles, CHO-K1; triangles, ZP128; squares, 128P13, a stable HsPEX13 transformant of ZP128. Relative free catalase activity is expressed as a percentage of the total activity measured in the presence of 1% Triton X-100 (5). The results represent the means of duplicate assays. (b) Biogenesis of peroxisomal proteins. Cell lysates (~105 cells) were subjected to SDS-PAGE and transferred to polyvinylidene difluoride membrane. Immunoblot analysis was done using rabbit antibodies to AOx and thiolase. Lanes 1 and 4, CHO-K1; lanes 2 and 5, ZP128; lanes 3 and 6, 128P13. Arrows show AOx components A, B and C; open and solid arrowheads indicate a larger precursor (P) and mature protein (M) of thiolase, respectively.

Table 2. Complementation of CHO cell mutants and PBD patient fibroblasts by HsPEX13
CHO Peroxisome- Patient fibroblasts Peroxisome- Gene
mutant positive clone     positive  
ZP128 25/30 (H)     PEX13
ZP150 +        
    A (VIII) -  
    B (VII) - PEX10
ZP92 - (C IV)   PEX6
    D (IX) - PEX16
Z24/ZP107 - (E I)   PEX1
Z65 - (F X)   PEX2
ZP139 -   (II)   PEX5
ZP109 -   (III)   PEX12
      VI -  
    G   -  
ZP110 -       PEX14
ZP114 -        
ZP119 - (J)     PEX19
Peroxisome-deficient CHO cell mutants (3,6,15), including novel CG-H mutants, ZP128 and ZP150 (this study), PEX6-defective ZP92 (14,22), PEX1-defective ZP107 (8,35), PEX2-impaired Z65 (9,37), PEX5-impaired ZP139 (21), PEX12-defective ZP109 (11,35,36), PEX14-deficient ZP110 (15,34), ZP114 (15) and PEX19-impaired ZP119 (6,12,20), as well as PBD patient fibroblasts of several CGs shown not to be represented by CHO mutants (3), i.e. CGs A, B, D and G of Gifu University, Gifu, Japan (6) and CG-VI of Kennedy-Krieger Institute, Baltimore, MD (6), were transfected with pUcD2Hyg·HsPEX13 and examined for peroxisome assembly by immunostaining with antisera to rat and human catalase, respectively, at 3 days post-transfection. Cells of CGs in parentheses were not used in this experiment. In ZP128 cells, peroxisome-positive colonies were counted in 30 colonies; in other cells: +, complemented; -, not complemented.

Abnormal biogenesis of peroxisomal enzymes was also complemented in 128P13 cells. All three polypeptide components of acyl-CoA oxidase (AOx) were evident in both 128P13 and CHO-K1 cells, as assessed by immunoblot analysis (Fig. 2B, b, lanes 1 and 3), whereas only the A component was seen in ZP128 (lane 2). PTS2-thiolase precursor was processed properly to the 41 kDa matured form in peroxisomes in 128P13, as in CHO-K1, but the 44 kDa precursor was stably present in ZP128 (Fig. 2B, b, lanes 4-6). As another typical phenotype, peroxisome-deficient mutants are killed specifically by the 12-(1[prime]-pyrene)dodecanoic acid (P12)/UV selection, as there is no synthesis of plasmalogens (14,26), whereas the P9OH/UV selection kills wild-type cells which incorporate this fatty alcohol analog into plasmalogen molecules (14,27). 128P13 cells showed P12/UV-resistant and P9OH/UV-sensitive phenotypes, as was the case for CHO-K1 cells (Table 3). Conversely, ZP128 was resistant to the P9OH/UV and sensitive to the P12/UV treatment.

Table 3. Properties of wild-type CHO-K1, ZP128 and HsPEX13-transfected ZP128 (128P13) cells
Cell Peroxisome Catalase latency P9OH/UV P12/UV
    (%) (%) (%)
CHO-K1 + 70 <0.01 67
ZP128 - 2.7 93 0.14
128P13 + 59 <0.01 79
Peroxisomes in cells were assessed morphologically by immunostaining of catalase. Catalase latency represents peroxisomal catalase, calculated from Figure 2B, as described (5). For determination of P12/UV or P9OH/UV resistance, 200 or 1 × 105 cells were inoculated into 60 mm dishes and selected (14). The numbers of colonies were counted in triplicate experiments and expressed as a percentage of that of an unselected control.

Taken together, these results indicate that PEX13 can fully complement the abnormalities in ZP128.

Dysfunction of Pex13p in CHO mutants

Isolation of Chinese hamster

PEX13. We isolated Chinese hamster (Cl) PEX13 by screening a CHO-K1 cDNA library with HsPEX13 as a probe. ClPEX13 was functionally active in complementing ZP128 (data not shown) and ZP150 (Fig. 2A, c) and encoded the 405 amino acid Pex13p (Fig. 3A). ClPex13p was longer by two amino acids than HsPex13p, with 93% amino acid identity, containing two hydrophobic, putative membrane-spanning regions (Fig. 3A, solid underlines) and a Src homology 3 (SH3) domain (28) (dashed underline), as found in yeast and human Pex13p (24,25,29,30). Two proline-rich regions (28) were located in the N-terminal part (Fig. 3, solid overlines), which were not evident in P.pastoris Pex13p (24).


Figure 3. Chinese hamster Pex13 protein and mutation analysis. (A) Amino acid sequence alignment of Chinese hamster and human Pex13 protein. The deduced amino acid sequence of Chinese hamster (Cl) Pex13p was compared with human (Hs) Pex13p. (-) is a space. Identical amino acids between species are shaded. Putative membrane-spanning segments are underlined; the dashed underline indicates a SH3 region, where conserved hydrophobic and acidic amino acids are marked by dots. Proline-rich regions are overlined. The solid arrowhead indicates the position of a missense mutation in one allele of ZP150; a 42 amino acid truncation in another allele is boxed (see below). The GenBank database accession no. for the Chinese hamster PEX13 gene is AB022191. (B) Mutation analysis of PEX13 in ZP150. (a) RT-PCR products from CHO-K1, ZP128 and ZP150 cells were separated by 1% agarose gel electrophoresis. Molecular markers are on the left. Open and solid arrowheads indicate 1.2 and 1.1 kb PCR products, respectively. (b) Partial sequence and deduced amino acid sequence of PEX13 cDNA isolated from CHO-K1 (left) and a mutant ZP150 (right) are shown. A point mutation at nucleotide 956 changes a codon for Ser319 (solid arrowhead in A) to a codon for Asn319. (c) Truncation of 126 nucleotides from positions at 793-918 (boxed) or 792-917 results in a 42 amino acid deletion from Asp265 to Lys306 (boxed in A). (C) Transfection of mutated Chinese hamster PEX13. Chinese hamster PEX13, ClPEX13 (a) or ZP150-derived PEX13, ClPEX13S319N (b) and ClPEX13e/s (c) were transfected into ZP128 cells. Cells were stained with anti-catalase antibody. Magnification, ×630; bar, 20 µm.

PEX13 in mutants.

On northern blotting, PEX13 mRNA was detected as an ~1.9 kb band in CHO-K1 and ZP150, but not in ZP128, implying alteration at a transcriptional level or rather rapid degradation of PEX13 mRNA in ZP128 (data not shown). To investigate dysfunction of Pex13p in ZP150, we isolated PEX13 from ZP150 by RT-PCR, where two different sizes of PCR product were obtained (Fig. 3B, a). Subsequent sequencing of the respective cDNA clones indicated a compound heterozygous mutation: in one allele, a mutation of nucleotide G to A at position 956 (the A of the initiating ATG being 1), in a codon for Ser319, resulting in a codon for Asn319 (Fig. 3B, b; see Fig. 3A, solid arrowhead), named ClPEX13S319N; in another allele, truncation of 126 nucleotides from residues 793-918 or 792-917, named ClPEX13e/s, resulted in a 42 amino acid deletion from Asp265 to Lys306, presumably because of a defective splicing (Fig. 3B, c; see Fig. 3A, box). Thus, dysfunction of the Pex13p caused by a missense point mutation and/or truncation is most likely the primary defect in ZP150. Little RT-PCR product was obtained from ZP128-derived mRNA (Fig. 3B, a), consistent with the finding on northern blot analysis.

Complementation of protein import by ClPEX13.

Expression of ClPEX13 complemented peroxisomal protein import of catalase in ZP128 cells (Fig. 3C, a), as was the case by HsPEX13 (Fig. 2A). To assess the impaired function of Pex13p, ZP150-derived ClPEX13S319N in pcDNA3.1/Zeo/TK vector, intentionally at a rather lower level of expression (see below), and ClPEX13e/s in pUcD2Hyg were transfected separately into ZP128. Catalase was present in the cytosol in most of the transfected cells (Fig. 3C, b), while a small number of particles were partly found, presumably due to a higher level of ClPEX13S319N expression as compared with that of ZP150 per se. This finding was more evident as assessed by using ClPEX13S319N in pUcD2Hyg with a more potent SR[alpha] promoter (data not shown). A similar result was likewise obtained when ZP150 was back-transfected with ClPEX13S319N (data not shown). ClPEX13e/s-transfected ZP128 cells showed catalase in the cytosol (Fig. 3C, c), as in ZP128 (see Fig. 1A, a), suggesting that ClPEX13e/s protein was biologically inactive. Taking these results together, we conclude that dysfunction of Pex13p caused by a S319N missense mutation and a 42 amino acid truncation is the primary defect in impaired peroxisome biogenesis in ZP150.

Characterization of PEX13 protein

Localization of Pex13p in peroxisomes was confirmed by several lines of evidence. Upon sucrose density gradient centrifugation of the rat liver light mitochondrial fraction, Pex13p was co-sedimented with peroxisomal marker proteins, including catalase, thiolase and a peroxisomal integral membrane protein, Pex12p (11) (data not shown). Rat peroxisomal Pex13p was resistant to the extraction with sodium carbonate (31) and was recovered in the detergent phase by Triton X-114 treatment (32), thereby indicating that Pex13p is an integral membrane protein (data not shown). N-terminally flag-tagged human Pex13p was co-localized with catalase when expressed in CHO-K1 cells and detected by immunofluorescent microscopy (Fig. 4a and b). After permeabilization with 25 µg/ml of digitonin, under which conditions plasma membranes are permeabilized selectively and intra-peroxisomal proteins are inaccessible to exogenous antibodies (11), flag-Pex13p, but not catalase, was discernible in a punctate staining pattern using anti-flag antibody (Fig. 4c and d). Therefore, the N-terminal part of Pex13p is exposed to the cytosol. A cytosolic orientation of the C-terminal part (24) was confirmed with antibody to the C-terminal 19 amino acid peptide of human Pex13p (data not shown). Moreover, endogenous Pex13p was also detectable and superimposable with the location of catalase in CHO-K1 (data not shown).


Figure 4. Intracellular localization and membrane topology of Pex13p. CHO-K1 cells transfected with flag-HsPEX13 were treated with 0.1% Triton X-100 (a and b) or 25 µg/ml of digitonin (c and d) by which the plasma membrane was specifically permeabilized (11,36). Cells were stained with antibodies to flag (a and c) and catalase (b and d). Note that Pex13p was detected after both types of treatmens. Magnification, ×630; bar, 20 µm.

DISCUSSION

After several cycles of the conventional mutant screening procedure, we isolated peroxisome-deficient CHO cell mutants ZP128 and ZP150 belonging to the PEX13-defective CG. ZP128 and ZP150 showed common properties such as absence from morphologically recognizable peroxisomes, no latency of catalase and high sensitivity to P12/UV treatment, despite normal synthesis of peroxisomal proteins, thereby representing typical somatic mammalian cell mutants defective in peroxisome biogenesis. Intriguingly, however, PTS1 proteins were partly imported to peroxisomal structures in ZP128 and ZP150. Fibroblasts from a CG-H patient also showed a similar phenotype (13).

It is noteworthy that the 364 amino acid Pex13p identified by Gould et al. (24) was exactly the same ORF that we isolated initially by functional complementation of ZP128, indicating that the translation product of PEX13 starting at the second ATG for Met40 was biologically active. Such truncated Pex13p is unlikely to be present in vivo, because the size of HsPex13p synthesized in vitro by coupled transcription-translation was indistinguishable from that of a protein detected by immunoblot of purified peroxisomes (data not shown).

Pex13p may function as a component of the matrix protein import machinery, e.g. PTS1 receptor (Pex5p) docking protein (24). In ZP150, Pex13p is mildly affected by a missense mutation at S319N, while a 42 amino acid deletion eliminates the biological activity of Pex13p, as assessed by back-transfection of each mutant ClPEX13 to ZP128. Loss of Pex13p in yeast eliminated the import of PTS1 and PTS2 proteins (24,29,30). These findings imply that the severity of the phenotype caused by the affected Pex13p in the mutants depends on the type of mutations. Interestingly, apparent import of PTS1 proteins, possibly PTS2 proteins as well, is noted in some ZP128 and ZP150 cells. Such a different phenotype within a single mutant cell clone may reflect temporally regulated binding of Pex13p to its ligands, including the Pex5p-PTS1 protein complex, at various stages of peroxisome biogenesis or cell division, etc. Moreover, failure in conversion of AOx-A to B and C components (Fig. 2B), even in PTS1-positive particles visible in ZP128 and ZP150, may reflect the dysfunction or impaired import of a putative processing protease. In ZP128 and ZP150, import of catalase is completely impaired. Catalase may be transported by a pathway involving Pex13p but presumably distinct from the one, if any, used for PTS1 import, as deduced from the finding that human catalase possesses a PTS1-like but distinct signal (33). Both alleles of the PEX13 gene appear to be expressed in ZP150, at least at the mRNA level, although the type of gene expression in CHO cells has been postulated to be hemizygotic. The level of PEX13 mRNA derived from each allele as well as of Pex13p with S319N and/or a truncation from Asp265 to Lys306 remain to be determined. It is of interest to note that a similar type of expression of both alleles was also noted in the PEX14 gene in CHO cell mutants (34).

Given the fact that Pex13p is inactivated by mutations, one at S319N in the SH3 domain and deletion of 42 amino acids including nearly half of the SH3 region, the SH3 domain is probably important for the biological activity of Pex13p, presumably involved in the interaction with the proline-rich region of proteins (28), including that of Pex13p itself. The SH3 domain in Pex13p was shown to interact with Pex5p (24,29,30). It is of interest to note, however, that recently identified human Pex13p appears to interact little with Pex5p in an overlay ligand-binding assay (25). It is also possible that the N-terminal part, shown in the present study to be exposed to the cytosol, plays an important role in such interaction. To address such issues, the structure and function relationship of Pex13p in mammalian cells should be delineated fully at the molecular level.

MATERIALS AND METHODS

Isolation of peroxisome-deficient CHO cell mutants and CG analysis

TKa cells, wild-type CHO-K1 cells transformed with rat PEX2 (9,35), were mutagenized and used for isolation of mutant cells defective in peroxisome biogenesis by the P9OH/UV method (27), as described (14,35). Peroxisomes in CHO cells and human fibroblasts were visualized by indirect immunofluorescence light microscopy, as described (14,35), using rabbit antibodies to rat liver catalase (5), human catalase (14), PTS1 peptide (21), rat thiolase (5) and 70 kDa peroxisomal integral membrane protein (5,6). Antigen-antibody complex was detected using fluorescein isothiocyanate-labeled sheep anti-rabbit immunoglobulin G antibody (Cappel). CG analysis was done by cDNA transfection (6) and cell fusion (14), as described.

Stable transfection of PEX13 and expression of flag-tagged Pex13p

An expression plasmid pUcD2Hyg·HsPEX13 was used to establish an HsPEX13-stable transformant 128P13, by selection with 200 µg/ml of hygromycin B (Sigma). An epitope was flag-tagged to the N-terminus of Pex13p by a PCR-based technique. HsPEX13 (nucleotide residues 4-506) was amplified using a forward primer HsPEX13.FLAG.F (5[prime]-CGGTCGACATGGATTATAAAGATGATGATGATAAAGCGTCCCAGCCGCCACCTCCC-3[prime]) and a reverse primer R6 (5[prime]-GAAAAGTGATTTGCTACATCCAAT-3[prime]). The PCR products were ligated into the SalI-NsiI site of pBlueScript SK(-)·HsPEX13, from which the SalI and SacI digest was then ligated into the SalI-KpnI site of pUcD2Hyg vector using SacI linker. Flag-Pex13p was detected using mouse monoclonal antibody to flag (Sigma) and Texas Red-labeled sheep anti-mouse IgG second antibody (Amersham Pharmacia Biotech).

Screening of a Chinese hamster cDNA library and mutation analysis

A 32P-labeled, 0.57 kb PstI-SphI fragment of HsPEX13 was used as a probe to screen 2.0 × 105 independent clones of a CHO-K1 cDNA library (21). One of two positive clones, ClPEX13, was digested with SalI and NotI and ligated into the SalI-NotI site of pCMVSPORT and a lower level expression vector pcDNA3.1/Zeo/TK that had been constructed by using pcDNA3.1/Zeo (Invitrogen) and thymidine kinase promoter derived from the pTK-Hyg vector (Clontech). Total RNA was obtained from ZP128 and ZP150 cells, as described (11). Reverse transcription was performed using total RNA (2 µg), oligo(dT) primer (0.5 µg) and Superscript II reverse transcriptase (Gibco BRL), in 50 µl. To amplify the full length of the PEX13 ORF, PCR was carried out with a pair of ClPEX13-specific PCR primers, sense GCGGCCGCATGGCGTCTCAGCCGCC and antisense GTCGACTCAAAGATCTTGTTTCTCTCCATTTTTC, including the initiation and termination codons (underlined), and template DNA (the reverse transcription product), as described (8,11). The AflII-BglII fragment from the ZP150-derived mutant allele, ClPEX13S319N cDNA, was placed into the AflII-BglII site of pCMVSPORT·ClPEX13. The KpnI-NotI fragment of ZP150-derived ClPEX13 in pCMVSPORT was ligated into the KpnI-NotI site of pcDNA3.1/Zeo/TK. The NotI-SalI fragment of a ZP150-derived, truncated form of PEX13, ClPEX13e/s, was ligated into the site of the pUcD2Hyg vector.

Other methods

The catalase latency assay using digitonin was performed as described (5). Western blot analysis was done with the respective rabbit antibodies and a second antibody, donkey anti-rabbit IgG antibody conjugated to horseradish peroxidase (Amersham Pharmacia Biotech), using ECL western blotting detection reagent (Amersham Pharmacia Biotech). P12/UV and P9OH/UV resistance was determined at 2 µM for 1.5 min and 6 µM for 2 min, respectively (11).

ABBREVIATIONS

AOx, acyl-CoA oxidase; CG, complementation group; CHO, Chinese hamster ovary; P9OH/UV, 9-(1[prime]-pyrene)nonanol/ultraviolet; P12, 12-(1[prime]-pyrene)dodecanoic acid; PBD, peroxisome biogenesis disorders; PTS1 and PTS2, peroxisome targeting signal types 1 and 2; SH3, Src homology 3.

ACKNOWLEDGEMENTS

We thank K. Tateishi for participating in the initial stage of this work, A. Tamura for technical assistance, K. Okumoto, M. Honsho, T. Tsukamoto and T. Osumi for comments, and R. Tanaka for secretarial work. This work was supported in part by a CREST grant (to Y.F.) from the Japan Science and Technology Corporation; Grants-in-Aid for Scientific Research (Y.F.) from the Ministry of Education, Science, Sports and Culture of Japan.

REFERENCES

1. . Lazarow, P.B. and Fujiki, Y. (1985) Biogenesis of peroxisomes. Annu. Rev. Cell. Biol., 1, 489-530. MEDLINE Abstract

2. . Titorenko, V.I. and Rachubinski, R.A. (1998) The endoplasmic reticulum plays an essential role in peroxisome biogenesis. Trends Biochem. Sci., 23, 231-233. MEDLINE Abstract

3. . Fujiki, Y. (1997) Molecular defects in genetic diseases of peroxisomes. Biochim. Biophys. Acta, 1361, 235-250. MEDLINE Abstract

4. . Kunau, W.-H. (1998) Peroxisome biogenesis from yeast to man. Curr. Opin. Microbiol., 1, 232-237. MEDLINE Abstract

5. . Tsukamoto, T., Yokota, S. and Fujiki, Y. (1990) Isolation and characterization of Chinese hamster ovary cell mutants defective in assembly of peroxisomes. J. Cell Biol., 110, 651-660. MEDLINE Abstract

6. . Kinoshita, N., Ghaedi, K., Shimozawa, N., Wanders, R.J.A., Matsuzono, Y., Imanaka, T., Okumoto, K., Suzuki, Y., Kondo, N. and Fujiki, Y. (1998) Newly identified Chinese hamster ovary cell mutants are defective in biogenesis of peroxisomal membrane vesicles (peroxisomal ghosts), representing a novel complementation group in mammals. J. Biol. Chem., 273, 24122-24130. MEDLINE Abstract

7. . Ghaedi, K., Itagaki, A., Toyama, R., Tamura, S., Matsumura, T., Kawai, A., Shimozawa, N., Suzuki, Y., Kondo, N. and Fujiki, Y. (1999) Newly identified Chinese hamster ovary cell mutants defective in peroxisome assembly represent complementation group A of human peroxisome biogenesis disorders and one novel group in mammals. Exp. Cell Res., 248, 482-488. MEDLINE Abstract

8. . Tamura, S., Okumoto, K., Toyama, R., Shimozawa, N., Tsukamoto, T., Suzuki, Y., Osumi, T., Kondo, N. and Fujiki, Y. (1998) Human PEX1 cloned by functional complementation on a CHO cell mutant is responsible for peroxisome-deficient Zellweger syndrome of complementation group I. Proc. Natl Acad. Sci. USA, 95, 4350-4355. MEDLINE Abstract

9. . Tsukamoto, T., Miura, S. and Fujiki, Y. (1991) Restoration by a 35K membrane protein of peroxisome assembly in a peroxisome-deficient mammalian cell mutant. Nature, 350, 77-81. MEDLINE Abstract

10. . Shimozawa, N., Tsukamoto, T., Suzuki, Y., Orii, T., Shirayoshi, Y., Mori, T. and Fujiki, Y. (1992) A human gene responsible for Zellweger syndrome that affects peroxisome assembly. Science, 255, 1132-1134. MEDLINE Abstract

11. . Okumoto, K., Shimozawa, N., Kawai, A., Tamura, S., Tsukamoto, T., Osumi, T., Moser, H., Wanders, R.J.A., Suzuki, Y., Kondo, N. and Fujiki, Y. (1998) PEX12, the pathogenic gene of group III Zellweger syndrome: cDNA cloning by functional complementation on a CHO cell mutant, patient analysis, and characterization of Pex12p. Mol. Cell. Biol., 18, 4324-4336. MEDLINE Abstract

12. . Matsuzono, Y., Kinoshita, N., Tamura, T., Shimozawa, N., Hamasaki, M., Ghaedi, K., Wanders, R.J.A., Suzuki, Y., Kondo, K. and Fujiki, Y. (1999) Human PEX19: cDNA cloning by functional complementation, mutation analysis in a Zellweger patient and potential role in peroxisomal membrane assembly. Proc. Natl Acad. Sci. USA, 96, 2116-2121. MEDLINE Abstract

13. . Shimozawa, N., Suzuki, Y., Zhang, Z., Imamura, A., Toyama, R., Mukai, S., Fujiki, Y., Tsukamoto, T., Osumi, T., Orii, T., Wanders, R.J.A. and Kondo, N. (1999) Nonsense and temperature-sensitive mutations in PEX13 are the cause of complementation group H of peroxisome biogenesis disorders. Hum. Mol. Genet., 8, 1077-1083. MEDLINE Abstract

14. . Shimozawa, N., Tsukamoto, T., Suzuki, Y., Orii, T. and Fujiki, Y. (1992) Animal cell mutants represent two complementation groups of peroxisome-defective Zellweger syndrome. J. Clin. Invest., 90, 1864-1870. MEDLINE Abstract

15. . Tateishi, K., Okumoto, K., Shimozawa, N., Tsukamoto, T., Osumi, T., Suzuki, Y., Kondo, N., Okano, I. and Fujiki, Y. (1997) Newly identified Chinese hamster ovary cell mutants defective in peroxisome biogenesis represent two novel complementation groups in mammals. Eur. J. Cell Biol., 73, 352-359. MEDLINE Abstract

16. . Tsukamoto, T., Hata, S., Yokota, S., Miura, S., Fujiki, Y., Hijikata, M., Miyazawa, S., Hashimoto, T. and Osumi, T. (1994) Characterization of the signal peptide at the amino terminus of the rat peroxisomal 3-ketoacyl-CoA thiolase precursor. J. Biol. Chem., 269, 6001-6010. MEDLINE Abstract

17. . Imamura, A., Tamura, S., Shimozawa, N., Suzuki, Y., Zhang, Z., Tsukamoto, T., Orii, T., Kondo, N., Osumi, T. and Fujiki, Y. (1998) Temperature-sensitive mutation in PEX1 moderates the phenotypes of peroxisome deficiency disorders. Hum. Mol. Genet., 7, 2089-2094. MEDLINE Abstract

18. . Zoeller, R.A., Allen, L.-A.H., Santos, M.J., Lazarow, P.B., Hashimoto, T., Tartakoff, A.M. and Raetz, C.R.H. (1989) Chinese hamster ovary cell mutants defective in peroxisome biogenesis. Comparison to Zellweger syndrome. J. Biol. Chem., 264, 21872-21878. MEDLINE Abstract

19. . Santos, M.J., Imanaka, T., Shio, H. and Lazarow, P.B. (1988) Peroxisomal integral membrane proteins in control and Zellweger fibroblasts. J. Biol. Chem., 263, 10502-10509. MEDLINE Abstract

20. . Shimozawa, N., Suzuki, Y., Zhang, Z., Imamura, A., Kondo, N., Kinoshita, N., Fujiki, Y., Tsukamoto, T., Osumi, T., Imanaka, T., Orii, T., Beemer, F., Mooijer, P., Dekker, C. and Wanders, R.J.A. (1998) Genetic basis of peroxisome assembly mutants of humans, CHO cells and yeast: identification of a new complementation group of peroxisome biogenesis disorders, absent from peroxisomal membrane ghosts. Am. J. Hum. Genet., 63, 1898-1903. MEDLINE Abstract

21. . Otera, H., Tateishi, K., Okumoto, K., Ikoma, Y., Matsuda, E., Nishimura, M., Tsukamoto, T., Osumi, T., Ohashi, K., Higuchi, O. and Fujiki, Y. (1998) Peroxisome targeting signal type 1 (PTS1) receptor is involved in import of both PTS1 and PTS2: studies with PEX5-defective CHO cell mutants. Mol. Cell. Biol., 18, 388-399. MEDLINE Abstract

22. . Tsukamoto, T., Miura, S., Nakai, T., Yokota, S., Shimozawa, N., Suzuki, Y., Orii, T., Fujiki, Y., Sakai, F., Bogaki, A., Yasumo, H. and Osumi, T. (1995) Peroxisome assembly factor-2, a putative ATPase cloned by functional complementation on a peroxisome-deficient mammalian cell mutant. Nature Genet., 11, 395-401. MEDLINE Abstract

23. . Poulos, A., Christodoulou, J., Chow, C.W., Goldblatt, J., Paton, B.C., Orii, T., Suzuki, Y. and Shimozawa, N. (1995) Peroxisomal assembly defects: clinical, pathologic, and biochemical findings in two patients in a newly identified complementation group. J. Pediatr., 127, 596-599. MEDLINE Abstract

24. . Gould, S.J., Kalish, J.E., Morrell, J.C., Bjorkman, J., Urquhart, A.J. and Crane, D.I. (1996) Pex13p is an SH3 protein of the peroxisome membrane and a docking factor for the predominantly cytoplasmic PTS1 receptor. J. Cell Biol., 135, 85-95. MEDLINE Abstract

25. . Fransen, M., Terlecky, S.R. and Subramani, S. (1998) Identification of a human PTS1 receptor docking protein directly required for peroxisomal protein import. Proc. Natl Acad. Sci. USA, 95, 8087-8092. MEDLINE Abstract

26. . Zoeller, R.A., Morand, O.H. and Raetz, C.R.H. (1988) A possible role for plasmalogens in protecting animal cells against photosensitized killing. J. Biol. Chem., 263, 11590-11596. MEDLINE Abstract

27. . Morand, O.H., Allen, L.-A.H., Zoeller, R.A. and Raetz, C.R.H. (1990) A rapid selection for animal cell mutants with defective peroxisomes. Biochim. Biophys. Acta, 1034, 132-141. MEDLINE Abstract

28. . Cohen, G.B., Ren, R. and Baltimore, D. (1995) Modular binding domains in signal transduction proteins. Cell, 80, 237-248. MEDLINE Abstract

29. . Elgersma, Y., Kwast, L., Klein, A., Voorn-Brouwer, T., van der Berg, M., Metzig, B., America, T., Tabak, H.F. and Distel, B. (1996) The SH3 domain of the Saccharomyces cerevisiae peroxisomal membrane protein Pex13p functions as a docking site for Pex5p, a mobile receptor for the import of PTS1-containing proteins. J. Cell Biol., 135, 97-109. MEDLINE Abstract

30. . Erdmann, R. and Blobel, G. (1996) Identification of Pex13p, a peroxisomal membrane receptor for the PTS1 recognition factor. J. Cell Biol., 135, 111-121. MEDLINE Abstract

31. . Fujiki, Y., Hubbard, A.L., Fowler, S. and Lazarow, P.B. (1982) Isolation of intracellular membranes by means of sodium carbonate treatment: application to endoplasmic reticulum. J. Cell Biol., 93, 97-102. MEDLINE Abstract

32. . Bodier, C. (1981) Phase separation of integral membrane proteins in Triton X-114 solution. J. Biol. Chem., 256, 1604-1607. MEDLINE Abstract

33. . Purdue, P.E. and Lazarow, P.B. (1996) Targeting of human catalase to peroxisomes is dependent upon a novel COOH-terminal peroxisomal targeting sequence. J. Cell Biol., 134, 849-862. MEDLINE Abstract

34. . Shimizu, N., Itoh, R., Hirono, Y., Otera, H., Ghaedi, K., Tateishi, K., Tamura, S., Okumoto, K., Harano, T., Mukai, S. and Fujiki, Y. (1999) The peroxin Pex14p: cDNA cloning by functional complementation on a Chinese hamster ovary cell mutant, characterization, and functional analysis. J. Biol. Chem., 274, 12593-12604. MEDLINE Abstract

35. . Okumoto, K., Bogaki, A., Tateishi, K., Tsukamoto, T., Osumi, T., Shimozawa, N., Suzuki, Y., Orii, T. and Fujiki, Y. (1997) Isolation and characterization of peroxisome-deficient Chinese hamster ovary cell mutants representing human complementation group III. Exp. Cell Res., 233, 11-20. MEDLINE Abstract

36. . Okumoto, K. and Fujiki, Y. (1997) PEX12 encodes an integral membrane protein of peroxisomes. Nature Genet., 17, 265-266. MEDLINE Abstract

37. . Tsukamoto, T., Shimozawa, N. and Fujiki, Y. (1994) Peroxisome assembly factor 1: nonsense mutation in a peroxisome-deficient Chinese hamster ovary cell mutant and deletion analysis. Mol. Cell. Biol., 14, 5458-5465. MEDLINE Abstract


+To whom correspondence should be addressed at: Department of Biology, Kyushu University Graduate School of Science, 6-10-1 Hakozaki, Higashi-ku, Fukuoka 812-8581, Japan. Tel: +81 92 642 2635; Fax: +81 92 642 4214; Email: yfujiscb{at}mbox.nc.kyushu-u.ac.jp


This page is run by Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, as part of the OUP Journals
Comments and feedback: jnl.info{at}oup.co.uk
Last modification:
Copyright© Oxford University Press, 1999.

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
JCBHome page
T. Matsuzaki and Y. Fujiki
The peroxisomal membrane protein import receptor Pex3p is directly transported to peroxisomes by a novel Pex19p- and Pex16p-dependent pathway
J. Cell Biol., December 29, 2008; 183(7): 1275 - 1286.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Mukai and Y. Fujiki
Molecular Mechanisms of Import of Peroxisome-targeting Signal Type 2 (PTS2) Proteins by PTS2 Receptor Pex7p and PTS1 Receptor Pex5pL
J. Biol. Chem., December 8, 2006; 281(49): 37311 - 37320.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
Y. Matsuzono, T. Matsuzaki, and Y. Fujiki
Functional domain mapping of peroxin Pex19p: interaction with Pex3p is essential for function and translocation
J. Cell Sci., September 1, 2006; 119(17): 3539 - 3550.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Matsuzono and Y. Fujiki
In Vitro Transport of Membrane Proteins to Peroxisomes by Shuttling Receptor Pex19p
J. Biol. Chem., January 6, 2006; 281(1): 36 - 42.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
N. Miyata and Y. Fujiki
Shuttling Mechanism of Peroxisome Targeting Signal Type 1 Receptor Pex5: ATP-Independent Import and ATP-Dependent Export
Mol. Cell. Biol., December 15, 2005; 25(24): 10822 - 10832.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
M. Maxwell, J. Bjorkman, T. Nguyen, P. Sharp, J. Finnie, C. Paterson, I. Tonks, B. C. Paton, G. F. Kay, and D. I. Crane
Pex13 Inactivation in the Mouse Disrupts Peroxisome Biogenesis and Leads to a Zellweger Syndrome Phenotype
Mol. Cell. Biol., August 15, 2003; 23(16): 5947 - 5957.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Honsho, T. Hiroshige, and Y. Fujiki
The Membrane Biogenesis Peroxin Pex16p. TOPOGENESIS AND FUNCTIONAL ROLES IN PEROXISOMAL MEMBRANE ASSEMBLY
J. Biol. Chem., November 8, 2002; 277(46): 44513 - 44524.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
H. Otera, K. Setoguchi, M. Hamasaki, T. Kumashiro, N. Shimizu, and Y. Fujiki
Peroxisomal Targeting Signal Receptor Pex5p Interacts with Cargoes and Import Machinery Components in a Spatiotemporally Differentiated Manner: Conserved Pex5p WXXXF/Y Motifs Are Critical for Matrix Protein Import
Mol. Cell. Biol., March 15, 2002; 22(6): 1639 - 1655.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Mukai, K. Ghaedi, and Y. Fujiki
Intracellular Localization, Function, and Dysfunction of the Peroxisome-targeting Signal Type 2 Receptor, Pex7p, in Mammalian Cells
J. Biol. Chem., March 8, 2002; 277(11): 9548 - 9561.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
K. Ghaedi, S. Tamura, K. Okumoto, Y. Matsuzono, and Y. Fujiki
The Peroxin Pex3p Initiates Membrane Assembly in Peroxisome Biogenesis
Mol. Biol. Cell, June 1, 2000; 11(6): 2085 - 2102.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
H. Otera, T. Harano, M. Honsho, K. Ghaedi, S. Mukai, A. Tanaka, A. Kawai, N. Shimizu, and Y. Fujiki
The Mammalian Peroxin Pex5pL, the Longer Isoform of the Mobile Peroxisome Targeting Signal (PTS) Type 1 Transporter, Translocates the Pex7p{middle dot}PTS2 Protein Complex into Peroxisomes via Its Initial Docking Site, Pex14p
J. Biol. Chem., July 7, 2000; 275(28): 21703 - 21714.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Matsumura, H. Otera, and Y. Fujiki
Disruption of the Interaction of the Longer Isoform of Pex5p, Pex5pL, with Pex7p Abolishes Peroxisome Targeting Signal Type 2 Protein Import in Mammals. STUDY WITH A NOVEL PEX5-IMPAIRED CHINESE HAMSTER OVARY CELL MUTANT
J. Biol. Chem., July 7, 2000; 275(28): 21715 - 21721.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Okumoto, I. Abe, and Y. Fujiki
Molecular Anatomy of the Peroxin Pex12p. RING FINGER DOMAIN IS ESSENTIAL FOR Pex12p FUNCTION AND INTERACTS WITH THE PEROXISOME-TARGETING SIGNAL TYPE 1-RECEPTOR Pex5p AND A RING PEROXIN, Pex10p
J. Biol. Chem., August 11, 2000; 275(33): 25700 - 25710.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Honsho and Y. Fujiki
Topogenesis of Peroxisomal Membrane Protein Requires a Short, Positively Charged Intervening-loop Sequence and Flanking Hydrophobic Segments. STUDY USING HUMAN MEMBRANE PROTEIN PMP34
J. Biol. Chem., March 16, 2001; 276(12): 9375 - 9382.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Toyama, R.
Right arrow Articles by Fujiki, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Toyama, R.
Right arrow Articles by Fujiki, Y.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?